指南与共识临床试验与 GCP新药、器械与细胞基因治疗研发

瑞德西韦治疗重症COVID-19的临床实践指南

Remdesivir for severe covid-19: a clinical practice guideline.
指南 / 共识 · BMJ · 2020-07-30

该指南由国际专家组采用GRADE方法制定,基于两项随机试验共1300名参与者的系统综述,对重症COVID-19使用瑞德西韦作出弱推荐,同时强烈支持继续招募患者进入正在进行的随机对照试验。

要点

  • 对重症COVID-19患者,弱推荐使用瑞德西韦。
  • 强烈支持继续招募患者进入正在进行的随机对照试验。
  • 证据确定性低,瑞德西韦可能缩短临床改善时间并可能降低死亡率。

核心结论

  • 指南对重症COVID-19使用瑞德西韦作出弱推荐,并强烈支持继续招募患者进入正在进行的随机对照试验。

研究设计与样本

  • 国际患者、临床医生和方法学家小组遵循可信指南标准,采用GRADE方法制定推荐。
  • 推荐基于一项关联的系统综述和网络Meta分析,该系统综述识别出两项随机试验共1300名参与者。

主要发现

  • 低确定性证据表明瑞德西韦可能有效缩短重症COVID-19患者的临床改善时间。
  • 低确定性证据表明瑞德西韦可能降低重症COVID-19患者的死亡率。
  • 瑞德西韦可能对需要有创机械通气没有重要影响。
  • 瑞德西韦可能对住院时间几乎没有或没有影响。

关键数值与推荐

  • 指南小组对重症COVID-19使用瑞德西韦作出弱推荐。
  • 指南小组推荐继续积极招募患者进入正在进行的随机对照试验以检验瑞德西韦。
  • 证据基于两项随机试验共1300名参与者,证据确定性低。

临床怎么用

  • 大多数重症COVID-19患者鉴于可能缩短临床改善时间,很可能选择瑞德西韦治疗。
  • 鉴于关键结局证据确定性低且不同视角、价值观和偏好可能改变决策,应结合具体情境考虑使用。
  • 应强烈支持继续招募患者进入正在进行的随机对照试验。

局限性

  • 关键结局的证据确定性低。
  • 不同视角、价值观和偏好可能改变关于瑞德西韦的决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CLINICAL QUESTION: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020. CURRENT PRACTICE: Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. After rapid market approval in the US, remdesivir is already being used in clinical practice. RECOMMENDATIONS: The guideline panel makes a weak recommendation for the use of remdesivir in severe covid-19 while recommending continuation of active enrolment of patients into ongoing randomised controlled trials examining remdesivir. HOW THIS GUIDELINE WAS CREATED: An international panel of patients, clinicians, and methodologists produced these recommendations in adherence with standards for trustworthy guidelines using the GRADE approach. The recommendations are based on a linked systematic review and network meta-analysis. The panel considered an individual patient perspective and allowed contextual factors (such as resources) to be taken into account for countries and healthcare systems. THE EVIDENCE: The linked systematic review (published 31 Jul 2020) identified two randomised trials with 1300 participants, showing low certainty evidence that remdesivir may be effective in reducing time to clinical improvement and may decrease mortality in patients with severe covid-19. Remdesivir probably has no important effect on need for invasive mechanical ventilation. Remdesivir may have little or no effect on hospital length of stay. UNDERSTANDING THE RECOMMENDATION: Most patients with severe covid-19 would likely choose treatment with remdesivir given the potential reduction in time to clinical improvement. However, given the low certainty evidence for critical outcomes and the fact that different perspectives, values, and preferences may alter decisions regarding remdesivir, the panel issued a weak recommendation with strong support for continued recruitment in randomised trials.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ. 2020. PMID: 32732352. doi:10.1136/bmj.m2924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。